PMID- 11161255
OWN - NLM
STAT- MEDLINE
DCOM- 20010322
LR  - 20190727
IS  - 0041-1132 (Print)
IS  - 0041-1132 (Linking)
VI  - 41
IP  - 1
DP  - 2001 Jan
TI  - PBPC mobilization with chemotherapy and G-CSF in patients with chronic myeloid 
      leukemia: quantification of bcr/abl-positive cells by interphase fluorescence in 
      situ hybridization and competitive PCR.
PG  - 111-6
AB  - BACKGROUND: Autografting of normal stem cells mobilized after chemotherapy is 
      increasingly used in chronic myeloid leukemia (CML). Thus, quantification of 
      possible contamination of progenitor cell apheresis with breakpoint cluster 
      region (bcr)/Abelson murine leukemia (abl)-positive cells is of great clinical 
      interest. STUDY DESIGN AND METHODS: Two molecular methods were compared to 
      quantify bcr/abl positivity in leukapheresis components obtained after mobilizing 
      chemotherapy in six patients with CML. To document the efficacy of in vivo 
      purging, the leukapheresis procedures were monitored with interphase fluorescence 
      in situ hybridization (FISH) and quantitative competitive PCR (QC-PCR) as a ratio 
      of bcr/abl:abl. RESULTS: From the first to the last leukapheresis, bcr/abl 
      positivity in FISH increased from a median of 11 percent to 33 percent. For 
      bcr/abl transcripts, a simultaneous increase in consecutive leukapheresis 
      procedures was seen. The median percentage of bcr cells in a bcr/abl:abl ratio 
      was 3.1 percent in the first apheresis. In the last apheresis after the 
      mobilization with mRNA, the QC-PCR showed a median of 19.5 percent. FISH and 
      QC-PCR showed a statistical significant increase of bcr/abl positivity from the 
      first to the last apheresis. CONCLUSIONS: Both FISH and QC-PCR were reliable 
      methods of quantifying bcr/abl positivity, and they allowed selection of the 
      optimal apheresis component for autologous transplantation. In both methods, a 
      significant increase in bcr/abl positivity was seen from the first to the last 
      leukapheresis. With FISH, results can be obtained within 24 hours. This method 
      may prevent additional contaminated leukapheresis in case of increasing 
      percentages of bcr/abl-positive cells.
FAU - Keil, F
AU  - Keil F
AD  - Children's Cancer Research Institute, St. Anna Kinderspital, Vienna, Austria. 
      felix.kiel@ akh-wie.ac.at
FAU - Mitterbauer, G
AU  - Mitterbauer G
FAU - Chen, X
AU  - Chen X
FAU - Haas, O A
AU  - Haas OA
FAU - Kalhs, P
AU  - Kalhs P
FAU - Lechner, K
AU  - Lechner K
FAU - Mannhalter, C
AU  - Mannhalter C
FAU - Moser, K
AU  - Moser K
FAU - Worel, N
AU  - Worel N
FAU - Pirc-Danoewinata, H
AU  - Pirc-Danoewinata H
FAU - Louda, N
AU  - Louda N
FAU - Loidolt, H
AU  - Loidolt H
FAU - Rabitsch, W
AU  - Rabitsch W
FAU - Greinix, H T
AU  - Greinix HT
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Transfusion
JT  - Transfusion
JID - 0417360
RN  - 0 (Oncogene Proteins)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 04079A1RDZ (Cytarabine)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.10.2 (Proto-Oncogene Proteins c-abl)
RN  - EC 2.7.11.1 (BCR protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-bcr)
RN  - ZRP63D75JW (Idarubicin)
SB  - IM
MH  - Adult
MH  - Cell Nucleus/metabolism
MH  - Chronic Disease
MH  - Cytarabine/pharmacology
MH  - Female
MH  - Granulocyte Colony-Stimulating Factor/pharmacology
MH  - Hematopoietic Stem Cells/drug effects/*metabolism
MH  - Humans
MH  - Idarubicin/pharmacology
MH  - In Situ Hybridization, Fluorescence
MH  - Interphase
MH  - Leukapheresis
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Oncogene Proteins/*metabolism
MH  - Polymerase Chain Reaction/methods
MH  - *Protein-Tyrosine Kinases
MH  - *Proto-Oncogene Proteins
MH  - Proto-Oncogene Proteins c-abl/*metabolism
MH  - Proto-Oncogene Proteins c-bcr
EDAT- 2001/02/13 11:00
MHDA- 2001/03/27 10:01
CRDT- 2001/02/13 11:00
PHST- 2001/02/13 11:00 [pubmed]
PHST- 2001/03/27 10:01 [medline]
PHST- 2001/02/13 11:00 [entrez]
AID - 10.1046/j.1537-2995.2001.41010111.x [doi]
PST - ppublish
SO  - Transfusion. 2001 Jan;41(1):111-6. doi: 10.1046/j.1537-2995.2001.41010111.x.